Pharma BD Deal Intelligence

Novartis AG / OBI Pharma, Inc

2026 · Licensing/Option · $2.0B · Complete

OBI Pharma entered a collaboration and license agreement with Novartis Pharma AG to develop next-generation antibody-drug conjugates using OBI's platform technologies (GlycOBI, EndoSymeOBI, HYPrOBI and GlycOBI DUO). Novartis receives worldwide exclusive rights to OBI's related patents and know-how for selected, undisclosed Novartis payload classes. OBI receives USD 30 million upfront and is eligible for development, regulatory and commercial milestones taking total potential deal value above USD 2 billion, plus tiered royalties on net sales.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →